Mrinal M. Gounder

ScholarGPS® ID: 29992771386168

Affiliation

Memorial Sloan Kettering Cancer Center, New York, United States

Affiliation History

Field

Medicine

Discipline

Oncology

Top Specialties

Metrics Summary

Publication Count

167

Predicted Citations

6,958

Predicted h-index

Ranking

Publications and Citation History

Publications based on Top Specialties

Types of Publication

Publications
Books
Patents
NIH/NSF

Add Delete
Developing knowledge, attitude and practice questionnaire in desmoid tumours (KAPID study): applying e-Delphi to rare diseases (journal article) Tansir, Ghazal \| Rastogi, Sameer \| Kaur, Simran \| Gounder, Mrinal \| Muta, Soumya ecancermedicalscience, volume 18 (2024). 10.3332/ecancer.2024.1715 Cite \| Source
Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy (journal article) Kazansky, Yaniv \| Cameron, Daniel \| Mueller, Helen S. \| Demarest, Phillip \| Zaffaroni, Nadia \| Arrighetti, Noemi \| Zuco, Valentina \| Kuwahara, Yasumichi \| Somwar, Romel \| Ladanyi, Marc \| ... \| Kentsis, Alex Cancer Discovery, volume 14, issue 6, pages 965-981 (2024). 10.1158/2159-8290.CD-23-0110 Cited by (3) \| Cite \| Source
Do patients with myxofibrosarcoma and undifferentiated pleomorphic sarcoma have different clinical outcomes to immune checkpoint blockade-based therapy? (journal article) Rosenbaum, Evan \| Seier, Kenneth \| Bradic, Martina \| Desir, Rhoena \| Kelly, Ciara Marie \| Movva, Sujana \| Avutu, Viswatej \| Banks, Lauren Baker \| Chan, Jason Earl \| Chi, Ping \| ... \| D'Angelo, Sandra P. Journal of Clinical Oncology, volume 42, issue 16_suppl, pages 11567-11567 (2024). 10.1200/JCO.2024.42.16_suppl.11567 Cite \| Source
Treatment of patients with dedifferentiated liposarcoma (DDLPS) with the MDM2–p53 antagonist brigimadlin and p53 function: A longitudinal analysis of circulating microRNAs (miRNAs) in a first-in-human phase Ia/Ib study. (journal article) Peltzer, Alexander \| LoRusso, Patricia \| Gounder, Mrinal M. \| Yamamoto, Noboru \| Somaiah, Neeta \| Lugowska, Iwona A. \| Moreno, Victor \| Teufel, Michael \| Jayadeva, Girish \| Hesse, Raphael \| ... \| Schöffski, Patrick Journal of Clinical Oncology, volume 42, issue 16_suppl, pages 11540-11540 (2024). 10.1200/JCO.2024.42.16_suppl.11540 Cite \| Source
Proteomic analysis in patients with dedifferentiated liposarcoma (DDLPS) in a phase Ia/Ib study of the MDM2–p53 antagonist brigimadlin. (journal article) Jaimes, Yarúa \| LoRusso, Patricia \| Sturm, Gregor \| Gounder, Mrinal M. \| Yamamoto, Noboru \| Somaiah, Neeta \| Lugowska, Iwona A. \| Moreno, Victor \| Peltzer, Alexander \| Teufel, Michael \| ... \| Schöffski, Patrick Journal of Clinical Oncology, volume 42, issue 16_suppl, pages 11541-11541 (2024). 10.1200/JCO.2024.42.16_suppl.11541 Cite \| Source
Preliminary results from FLAGSHP-1: A phase 1 study of ERAS-601 as a monotherapy or in combination with cetuximab in patients (pts) previously treated for advanced chordoma. (journal article) Gounder, Mrinal M. \| Rosen, Ezra \| Parikh, Aparna Raj \| Conley, Anthony Paul \| Hong, David S. \| Sheth, Siddharth \| Mai, Nicholas \| Sgroe, Erica \| Mitchell, Ryan \| Picard, Roxana \| ... \| Cote, Gregory Michael Journal of Clinical Oncology, volume 42, issue 16_suppl, pages 11522-11522 (2024). 10.1200/JCO.2024.42.16_suppl.11522 Cite \| Source
57MO Impact of nirogacestat (niro) on patient-reported outcomes (PROs) in adults with desmoid tumor with a best overall response (BOR) of stable disease (SD): Post hoc analysis from the DeFi study (journal article) Stacchiotti, S. \| Chawla, S.P. \| Chugh, R. \| D'Amato, G. \| Gounder, M. \| Ratan, R. \| van der Graaf, W.T.A. \| Amoruccio, V. \| Bell, T. \| Cho, S. \| Schöffski, P. ESMO Open, volume 9 (2024). 10.1016/j.esmoop.2024.102447 Cite \| Source
PDGFRβ Signaling Cooperates with β-Catenin to Modulate c-Abl and Biologic Behavior of Desmoid-Type Fibromatosis (journal article) Hu, Jia \| Hameed, Meera R. \| Agaram, Narasimhan P. \| Whiting, Karissa A. \| Qin, Li-Xuan \| Villano, Anthony M. \| O'Connor, Rachael B. \| Rozenberg, Julian M. \| Cohen, Sonia \| Prendergast, Katherine \| ... \| Crago, Aimee M. Clinical Cancer Research, volume 30, issue 2, pages 450-461 (2024). 10.1158/1078-0432.CCR-23-2313 Cited by (1) \| Cite \| Source
Capturing Patient Voice to Improve Outcomes That Matter to Patients with Desmoid Tumor (journal article) Kasper, Bernd \| Gounder, Mrinal \| Hernandez, Lynne \| Baumgarten, Christina \| Ratan, Ravin Cancer Management and Research, volume Volume 16 (2024). 10.2147/CMAR.S362694 Cite \| Source
Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas (journal article) Rosenbaum, Evan \| Seier, Kenneth \| Bradic, Martina \| Kelly, Ciara \| Movva, Sujana \| Nacev, Benjamin A. \| Gounder, Mrinal M. \| Keohan, Mary L. \| Avutu, Viswatej \| Chi, Ping \| ... \| D'Angelo, Sandra P. Cancer Research Communications, volume 3, issue 10, pages 2118-2125 (2023). 10.1158/2767-9764.CRC-22-0140 Cited by (3) \| Cite \| Source
674P Response of thrombopoietin receptor agonists in MDM2 inhibitor induced thrombocytopenia (journal article) DeMatteo, R. \| Sgroe, E. \| Merrill, M.B. \| Gounder, M. \| Liu, D. Annals of Oncology, volume 34 (2023). 10.1016/j.annonc.2023.09.1860 Cite \| Source
673P A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2–p53 antagonist brigimadlin (BI 907828) in patients (pts) with solid tumours (journal article) Schoeffski, P. \| Lorusso, P. \| Yamamoto, N. \| Lugowska, I. \| Moreno Garcia, V. \| Lauer, U. \| Hu, C. \| Jayadeva, G. \| Lahmar, M. \| Gounder, M. Annals of Oncology, volume 34 (2023). 10.1016/j.annonc.2023.09.1859 Cite \| Source
1929P phase II results from the RINGSIDE phase II/III trial of AL102 for treatment of desmoid tumors (journal article) Kasper, B. \| Gounder, M. \| Chugh, R. \| Agulnik, M. \| Van Tine, B.A. \| Andelkovic, V. \| Choy, E. \| Lewin, J. \| Ratan, R. \| Gordon, G. \| ... \| Jones, R.L. Annals of Oncology, volume 34 (2023). 10.1016/j.annonc.2023.09.1158 Cited by (1) \| Cite \| Source
GOunder/Desmoid Tumor Research Foundation DEsmoid Symptom/Impact Scale (GODDESS©): psychometric properties and clinically meaningful thresholds as assessed in the Phase 3 DeFi randomized controlled clinical trial (journal article) Gounder, Mrinal M. \| Atkinson, Thomas M. \| Bell, Timothy \| Daskalopoulou, Christina \| Griffiths, Pip \| Martindale, Moriah \| Smith, L. Mary \| Lim, Allison Quality of Life Research, volume 32, issue 10, pages 2861-2873 (2023). 10.1007/s11136-023-03445-7 Cited by (2) \| Cite \| Source
The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study (journal article) LoRusso, Patricia \| Yamamoto, Noboru \| Patel, Manish R. \| Laurie, Scott A. \| Bauer, Todd M. \| Geng, Junxian \| Davenport, Teffany \| Teufel, Michael \| Li, Jian \| Lahmar, Mehdi \| Gounder, Mrinal M. Cancer Discovery, volume 13, issue 8, pages 1802-1813 (2023). 10.1158/2159-8290.CD-23-0153 Cited by (26) \| Cite \| Source
Longitudinal mutational analysis of TP53 in plasma circulating tumor DNA (ctDNA) in patients (pts) with solid tumors in a phase I study of BI 907828, an MDM2–p53 antagonist. (journal article) Peltzer, Alexander \| Hesse, Raphael \| Gounder, Mrinal M. \| Yamamoto, Noboru \| Patel, Manish R. \| Laurie, Scott \| Bauer, Todd Michael \| Teufel, Michael \| Geng, Junxian \| LoRusso, Patricia Journal of Clinical Oncology, volume 41, issue 16_suppl, pages 3036-3036 (2023). 10.1200/JCO.2023.41.16_suppl.3036 Cite \| Source
A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma. (journal article) Movva, Sujana \| Avutu, Viswatej \| Chi, Ping \| Dickson, Mark Andrew \| Gounder, Mrinal M. \| Kelly, Ciara Marie \| Keohan, Mary Louise \| Meyers, Paul A. \| Cohen, Seth M. \| Hensley, Martee Leigh \| ... \| D'Angelo, Sandra P. Journal of Clinical Oncology, volume 41, issue 16_suppl, pages 11517-11517 (2023). 10.1200/JCO.2023.41.16_suppl.11517 Cited by (5) \| Cite \| Source
RINGSIDE phase 2/3 trial of AL102 for treatment of desmoid tumors (DT): Phase 2 results. (journal article) Gounder, Mrinal M. \| Jones, Robin Lewis \| Chugh, Rashmi \| Agulnik, Mark \| Singh, Arun S. \| Van Tine, Brian Andrew \| Andelkovic, Vladimir \| Choy, Edwin \| Lewin, Jeremy Howard \| Ratan, Ravin \| ... \| Kasper, Bernd Journal of Clinical Oncology, volume 41, issue 16_suppl, pages 11515-11515 (2023). 10.1200/JCO.2023.41.16_suppl.11515 Cited by (4) \| Cite \| Source
Impact of nirogacestat on pain, a key symptom in patients with desmoid tumors (DT): Results from the phase 3 DeFi study. (journal article) Van Der Graaf, Winette T.A. \| Gounder, Mrinal M. \| Ratan, Ravin \| Ivanescu, Cristina \| Marcus, James \| Bell, Timothy \| Lim, Allison \| Smith, L. Mary \| Oton, Ana Belen \| Alcindor, Thierry \| ... \| Kasper, Bernd Journal of Clinical Oncology, volume 41, issue 16_suppl, pages 11564-11564 (2023). 10.1200/JCO.2023.41.16_suppl.11564 Cite \| Source
A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients (pts) with solid tumors: Safety and efficacy in patients with dedifferentiated liposarcoma (DDLPS). (journal article) LoRusso, Patricia \| Gounder, Mrinal M. \| Yamamoto, Noboru \| Patel, Manish R. \| Bauer, Todd Michael \| Geng, Junxian \| Sailer, Reinhard \| Tang, Yuefen \| Jayadeva, Girish \| Schöffski, Patrick Journal of Clinical Oncology, volume 41, issue 16_suppl, pages 11554-11554 (2023). 10.1200/JCO.2023.41.16_suppl.11554 Cited by (3) \| Cite \| Source

Title	Investigators	Year	Cost	Agency
Phase III Randomized Blinded Trial of Sorafenib vs Placebo in Desmoid Tumor A091105/116279 12/2013	Gounder, Mrinal	2018	$153,278	FOOD AND DRUG ADMINISTRATION
Phase III Randomized Blinded Trial of Sorafenib vs Placebo in Desmoid Tumor A091105/116279 12/2013	Gounder, Mrinal	2017	$284,221	FOOD AND DRUG ADMINISTRATION
Phase III Randomized Blinded Trial of Sorafenib vs Placebo in Desmoid Tumor A091105/116279 12/2013	Gounder, Mrinal	2016	$286,378	FOOD AND DRUG ADMINISTRATION
Phase III Randomized Blinded Trial of Sorafenib vs Placebo in Desmoid Tumor A091105/116279 12/2013	Gounder, Mrinal	2015	$150,855	FOOD AND DRUG ADMINISTRATION